Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add filters








Language
Year range
1.
Braz. J. Pharm. Sci. (Online) ; 58: e20263, 2022. tab, graf
Article in English | LILACS | ID: biblio-1403679

ABSTRACT

Abstract The objective of the study was to evaluate the gelling properties of Dillenia indica mucilage in benzyl benzoate emulgel formulation. Mucilage was extracted from the fruits of Dillenia indica using established methods and characterized by rheology and swelling. Emulsion (F1) was prepared using the continental emulsification method. Gelling agents (2 %w /v) were prepared by dispersing in distilled water with constant stirring at a moderate speed using a magnetic stirrer. F1 was added to the gel (0-75 %w /w) to obtain emulgel formulations and evaluated using viscosity, globule size, pH, release profiles and kinetic modeling. Data were expressed as mean ± SD, and similarity factor (f2) was used to compare all formulations. Formulation viscosity was significantly higher with carbopol than with Dillenia; globule sizes increased with concentration of gelling agents, and pH reduced as the concentration of Dillenia increased. All formulations showed controlled release properties with t80 ranging between 114 and 660 min. The release was governed by Korsmeyer-Peppas model. Formulation F5 prepared with 50 % Dillenia showed highest similarity to F4 prepared with 75 %w /w carbopol. Dillenia indica demonstrated acceptable gelling properties comparable with that of carbopol and could be improved for use in emulgel formulations.


Subject(s)
Benzoates/administration & dosage , Dilleniaceae/anatomy & histology , Gelling Agents , Plant Mucilage/agonists , Emulsions/analysis , Methods
2.
Braz. J. Pharm. Sci. (Online) ; 55: e17511, 2019. tab, graf, ilus
Article in English | LILACS | ID: biblio-1039070

ABSTRACT

Ocular allergy is one of the most common disorders of the eye surface. Following diagnosis this condition is typically treated with preparations containing antihistamines. However, anatomy of the eye and its natural protective mechanisms create challenges for ocular drug delivery. Rapid elimination of antihistamine substances due to short residency times following application can lead to insufficient treatment of ocular allergies. With this in mind, the aim of this study was to prepare a controlled ocular delivery system to extend the retention time of olopatadine hydrochloride (OLO) and in doing so to reduce the need for frequent application. We developed extended-release ocular in situ gelling systems for which in vivo retention times were determined in sheep following in vitro characterization and cytotoxicity studies. In vivo results were then compared to commercially available Patanol eye drops. the transparent gels formulated using appropriate amounts of polymers and having longer ocular retention times appear to be a viable alternative to commercially available eye drops.


Subject(s)
Animals , Male , Female , In Vitro Techniques , Eye Diseases/pathology , Olopatadine Hydrochloride/adverse effects , Gelling Agents , Lubricant Eye Drops/pharmacokinetics
3.
Braz. j. pharm. sci ; 49(3): 537-547, July-Sept. 2013. ilus
Article in English | LILACS | ID: lil-689907

ABSTRACT

Stigmasterol - a plant sterol with several pharmacological activities - is susceptible to oxidation when exposed to air, a process enhanced by heat and humidity. In this context, microencapsulation is a way of preventing oxidation, allowing stigmasterol to be incorporated into various pharmaceutical forms while increasing its absorption. Microparticles were obtained using a blend of polymers of sodium alginate, starch and chitosan as the coating material through a one-stage process using the external gelation technique. Resultant microparticles were spherical, averaging 1.4 mm in size. Encapsulation efficiency was 90.42% and method yield 94.87%. The amount of stigmasterol in the oil recovered from microparticles was 9.97 mg/g. This technique proved feasible for the microencapsulation of stigmasterol.


O estigmasterol, um fitoesterol com diversas atividades farmacológicas, é suscetível à oxidação quando exposto ao ar, calor e umidade. Neste contexto, a microencapsulação é uma forma de proteção contra oxidação, permitindo a incorporação do estigmasterol em diversas formas farmacêuticas e aumentar sua absorção. As micropartículas foram obtidas por gelificação iônica externa, em uma etapa, utilizando como revestimento polímeros naturais de alginato de sódio, amido de milho e quitosana. As micropartículas apresentaram formato esférico com tamanho aproximado de 1,4 mm. O rendimento foi de 94,87% e a eficiência média de encapsulação de 90,42%. A quantidade de estigmasterol no óleo recuperado das micropartículas foi de 9,97 mg/g. O método mostrou-se viável para a microencapsulação do estigmasterol.


Subject(s)
Stigmasterol/analysis , Alginates/classification , Gelling Agents , Starch , Chitosan , Drug Compounding/classification , /classification
4.
Braz. j. pharm. sci ; 49(4): 873-888, Oct.-Dec. 2013. ilus, tab
Article in English | LILACS | ID: lil-704120

ABSTRACT

The objective of this study was to formulate an oral sustained release delivery system of sodium diclofenac(DS) based on sodium alginate (SA) as a hydrophilic carrier in combination with chitosan (CH) and sodium carboxymethyl cellulose (SCMC) as drug release modifiers to overcome the drug-related adverse effects and to improve bioavailability. Microspheres of DS were prepared using an easy method of ionotropic gelation. The prepared beads were evaluated for mean particle size, entrapment efficiency, swelling capacity, erosion and in-vitro drug release. They were also subjected to various studies such as Fourier Transform Infra-Red Spectroscopy (FTIR) for drug polymer compatibility, Scanning Electron Microscopy for surface morphology, X-ray Powder Diffraction Analysis (XRD) and Differential Scanning Calorimetric Analysis (DSC) to determine the physical state of the drug in the beads. The addition of SCMC during the preparation of polymeric beads resulted in lower drug loading and prolonged release of the DS. The release profile of batches F5 and F6 showed a maximum drug release of 96.97 ± 0.356% after 8 h, in which drug polymer ratio was decreased. The microspheres of sodium diclofenac with the polymers were formulated successfully. Analysis of the release profiles showed that the data corresponds to the diffusion-controlled mechanism as suggested by Higuchi.


O objetivo deste estudo foi elaborar um sistema de entrega de oral de liberação sustentada de diclofenaco sódico (DS) com base em alginato de sódio (SA), como um transportador hidrofílico em combinação com quitosana (CH) e carboximetilcelulose de sódio (SCMC) como modificadores de liberação de fármaco para diminuir os efeitos adversos e melhorar a biodisponibilidade. Prepararam-se microesferas de DS usando um método fácil de geleificação ionotrópica. Avaliaram-se os grânulos preparados quanto ao tamanho médio de partícula, eficiência de compressão, inchaço in vitro, erosão e capacidade de liberação de fármacos. Estes tammbém foram submetidos a vários estudos, como espectrometria no infravermelho com transformada de Fourier (FTIR) para compatibilidade de fármaco e polímero, microscopia eletrônica de varredura para morfologia de superfície, análise de difração de raios-X (XRD) do pós e análise calorimétrica diferencial de varredura (DSC) para determinar o estado físico do fármaco nos grânulos. A adição de SCMC durante a preparação de grânulos do polímero resultou em fármacos com menor carga de fármaco e liberação prolongada do DS. O perfil de liberação dos lotes F5 e F6 apresentou máximo de fármaco liberado de 96,97±0,356% após 8 h após o que a proporção do fármaco no polímero foi diminuída. As microesferas de diclofenaco de sódio com os polímeros foram formuladas com sucesso. A análise dos perfis de liberação mostrou que os dados correspondem ao mecanismo de difusão controlada, como sugerido por Higuchi.


Subject(s)
Diclofenac/analysis , Microspheres , Polymers/analysis , Alginates/analysis , Gelling Agents
5.
Braz. j. pharm. sci ; 46(4): 785-793, Oct.-Dec. 2010. ilus, graf, tab
Article in English | LILACS | ID: lil-622879

ABSTRACT

The objective of this study was to develop a sustained release dosage form of Trimetazidine dihydrochloride (TMZ) using a natural polymeric carrier prepared in a completely aqueous environment. TMZ was entrapped in calcium alginate beads prepared with sodium alginate by the ionotropic gelation method using calcium chloride as a crosslinking agent. The drug was incorporated either into preformed calcium alginate gel beads (sequential method) or incorporated simultaneously during the gelation stage (simultaneous method). The beads were evaluated for particle size and surface morphology using optical microscopy and SEM, respectively. Beads produced by the sequential method had higher drug entrapment. Drug entrapment in the sequential method was higher with increased CaCl2 and polymer concentration but lower with increased drug concentration. In the simultaneous method, drug entrapment was higher when polymer and drug concentration were increased and also rose to a certain extent with increase in CaCl2 concentration, where further increase resulted in lower drug loading. FTIR studies revealed that there is no interaction between drug and CaCl2. XRD studies showed that the crystalline drug changed to an amorphous state after formulation. Release characteristics of the TMZ loaded calcium alginate beads were studied in enzyme-free simulated gastric and intestinal fluid.


O objetivo deste estudo foi desenvolver forma de liberação controlada de dicloridrato de trimetazidina (TMZ) utilizando transportador plomérico natural em ambiente completamente aquoso. A TMZ foi presa em pérolas de alginato de cálcio preparadas com alginato de sódio pelo método de gelatinização ionotrópica, usando cloreto de cálcio como agente de formação de ligações cruzadas. O fármaco foi incorporado nas pérolas de gel de alginato de cálcio (método sequencial) ou incorporado, simultaneamente, durante o estágio de gelificação (método simultâneo). As pérolas foram avaliadas quanto ao tamanho das partículas e morfologia da superfície utilizando microscopia óptica de SEM, respectivamente. As pérolas produzidas pelo método sequencial apresentaram maior capacidade de inclusão. No método sequencial, a inclusão de fármaco foi maior com o aumento de CaCl2 e da concentração do plímero, mas menor com o aumento da concentração de fármaco. No método simultâneo, a inclusão de fármaco foi mais alta quando as concentrações de fármaco e plímero foram aumentadas e, também, atingiram certa extensão com aumento na concentração de CaCl2, cujo aumento posterior resultou em carga menor de fármaco. Estudos de FTIR revelaram que não há interação entre fármaco e CaCl2. Estudos de XRD mostraram que o fármaco mudou do estado cristalino para o amorfo após a formulação. As características de liberação de TMZ das pérolas carregadas com alginato de cálcio foram estudadas em fluidos simulados, gástrico e intestinal, livres de enzima.


Subject(s)
Calcium/pharmacology , Capsules/analysis , Capsules/pharmacokinetics , Capsules/chemistry , In Vitro Techniques , Drug Design , Gelling Agents , Chemistry, Pharmaceutical/methods , Sodium , Trimetazidine/pharmacology
6.
Braz. j. pharm. sci ; 46(1): 109-114, Jan.-Mar. 2010. graf, tab
Article in English | LILACS | ID: lil-548740

ABSTRACT

Dermatological inflammatory diseases such as atopic dermatitis, psoriasis and seborrhoeic dermatitis often affect the scalp and the eyebrows. Although there are many dosage forms available, these are particularly critical anatomic regions for application of topical formulations because of the presence of hair. Lotions are therefore the recommended type of drug delivery system for these areas. The presence of hair may limit the application and thus the acceptability of the formulation and its compliance. Because of its low apparent viscosity, lotion application is unpleasant. Gels, given their consistency and adhesiveness, are a suitable alternative to lotions in this situation. The aim of this study was to formulate a stable gel containing mometasone furoate, which is an anti-inflammatory and anti-pruritic corticosteroid, in order to improve topical treatment of scalp dermatitis. In this study, pharmaceutical development, physical-chemical characterization, stability and in vitro permeation studies were performed. In terms of the pH, viscosity, assay and macroscopic and microbiological properties, the gel was stable over the period of study. The in vitro permeation studies allowed the characterization of the mometasone furoate permeation profile for the gel through different membranes. Mometasone furoate presented a slow permeation through the skin. This gel appears safe for topical application.


Afecções dermatológicas do tipo inflamatório como a dermatite atópica, psoríase e dermatite seborreica, afetam freqüentemente o couro cabeludo e sobrancelhas. Apesar de existirem várias formas farmacêuticas para o seu tratamento, apenas as loções são indicadas para estas zonas, mas devido à baixa viscosidade, a aplicação de loções torna-se desagradável. Os geles, pela maior consistência e capacidade de adesão, apresentam-se como alternativa nesta situação. Neste trabalho procedeu-se ao desenvolvimento galênico de um gel com furoato de mometasona, que é um potente corticóide de última geração, com um rácio melhorado de risco/benefício. Foram avaliadas as características físico-químicas, a estabilidade e foram realizados ensaios de permeação in vitro. O gel obtido apresenta características organolépticas e reológicas adequadas ao fim a que se destina tendo-se apresentado estável química, física e microbiologicamente durante o tempo do ensaio. Os estudos de permeação in vitro permitiram caracterizar a formulação através de diferentes membranas. A membrana biológica (pele) não permite uma grande permeação do fármaco o que poderá sugerir que esta formulação é segura para aplicação tópica.


Subject(s)
Drug Stability , Dermatitis/therapy , Gelling Agents , Scalp , Technological Development , Permeability , Pharmacological Phenomena
SELECTION OF CITATIONS
SEARCH DETAIL